Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pasi Antero Janne, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Pasi Janne and Jennifer Temel.
Connection Strength

0.398
  1. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6.
    View in: PubMed
    Score: 0.098
  2. Jackman DM, Yeap B, Lucca J, Ostler PA, Morse LK, Fidias P, Lynch TJ, Temel J, Johnson BE, Janne PA. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7168.
    View in: PubMed
    Score: 0.095
  3. Jackman D, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Johnson BE, Janne PA. Phase II study of the EGFR tyrosine kinase erlotinib in patients = 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7148.
    View in: PubMed
    Score: 0.088
  4. Johnson BE, Lucca J, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Liu G, Janne PA. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7080.
    View in: PubMed
    Score: 0.083
  5. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.